Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 14 May 2026 for Apellis Pharmaceuticals, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Keli Walbert: trading record in brief
Keli Walbert, listed as senior executive, appears in our data through filings on Apellis Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 8 January 2025 to 14 May 2026, the count stands at 3 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 14 May 2026: a transaction, in Apellis Pharmaceuticals, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Keli Walbert
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
17,051 sharesCommon StockSEC:0001193125-26-224601:0
7,961 shares0Common StockSEC:0001492422-26-000009:0
9,090 shares0Common StockSEC:0001127602-25-001073:0
3 of 3 declarations
